Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.

Drugs of today (Barcelona, Spain : 1998) - 1 Oct 2009

Walsh Garry M

Abstract excerpt

Familial cold-induced autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease make up cryopyrin-associated periodic syndromes (CAPS). These are autoinflammatory inherited disorders caused by autosomal dominant gain-of-function mutations in the NLRP3 ge...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cryopyrin-Associated Periodic Syndromes

Share to Interleukin-1beta

Share to Mutation

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Source

Identifiers

PMID: 20069137
DOI: 1396674/dot.2009.45.10.1416583

Genes

CAPS
NLRP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20069137-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.PMID 20069137Read ↗

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.Semantic proximity Read ↗

Use of canakinumab in the cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Pharmacological treatment options for cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.Semantic proximity Read ↗

Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: diagnosis and management.Semantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease.Semantic proximity Read ↗

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.Semantic proximity Read ↗

Treatment of autoinflammatory syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.